Abstract
For men with advanced prostate cancer undergoing androgen-deprivation therapy (ADT), toremifene might counter side effects associated with this treatment, according to two multicentre studies presented at the 3rd Prostate Cancer Symposium (Orlando, FL, USA; Feb 22–24, 2007). Increased fracture risk, and more recently, increased risk of cardiovascular disease associated with ADT have been previously reported.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
